24 results on '"Yao, Li-Chin"'
Search Results
2. Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
3. Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
4. Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
5. Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
6. Data from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
7. Supplementary Methods from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
8. Supplementary Figure Legends 1-2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
9. Supplementary Figure 2 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
10. Supplementary Table 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
11. Supplementary Figure 1 from VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
12. Abstract 2875: Development of a new tumor-bearing humanized mouse model to evaluate the efficacy and toxicity of bispecific T cell engagers
13. Abstract 1640: Enhanced development of functional human innate immune cells in a novel FLT3nullNSG mouse strain expressing human FLT3L
14. Abstract 1338: Humanized mouse model for in vivo evaluation of bispecific antibody efficacy
15. Abstract 5619: PBMC humanized NSG-(KbDb)null (IA)null mouse model to evaluate immune-oncology drug efficacy
16. Abstract 5186: Human stem cell humanized mouse model for in vivo evaluation of bispecific antibody efficacy and drug-induced cytokine release
17. Abstract 3354: Preclinical evaluation of potential cytokine release syndrome and efficacy of a BCMA-CD3 bispecific antibody for the treatment of multiple myeloma in humanized mice
18. Abstract 3320: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cells based immunology
19. Abstract B72: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cell-based immunotherapy
20. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
21. Abstract 5676: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: An improved immuno-oncology platform
22. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
23. Abstract LB-C01: Patient-derived tumor xenografts in humanized NSG-SGM3 mice: A new immuno-oncology platform
24. VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.